These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 3157511)

  • 1. Follow-up of prolactin levels in long-term oestrogen-treated male-to-female transsexuals with regard to prolactinoma induction.
    Gooren LJ; Harmsen-Louman W; van Kessel H
    Clin Endocrinol (Oxf); 1985 Feb; 22(2):201-7. PubMed ID: 3157511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolactin levels and pituitary enlargement in hormone-treated male-to-female transsexuals.
    Asscheman H; Gooren LJ; Assies J; Smits JP; de Slegte R
    Clin Endocrinol (Oxf); 1988 Jun; 28(6):583-8. PubMed ID: 2978262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estrogen-induced prolactinoma in a man.
    Gooren LJ; Assies J; Asscheman H; de Slegte R; van Kessel H
    J Clin Endocrinol Metab; 1988 Feb; 66(2):444-6. PubMed ID: 3339116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of cyproterone acetate alone and in combination with ethinylestradiol on the hypothalamic pituitary adrenal axis, prolactin and growth hormone release in male-to-female transsexuals.
    de Vries CP; Gooren LJ; van der Veen EA
    Horm Metab Res; 1986 Mar; 18(3):203-5. PubMed ID: 2939014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Somatostatin inhibits prolactin release from the lactotroph primed with oestrogen and cyproterone acetate in man.
    Gooren LJ; Harmsen-Louman W; van Kessel H
    J Endocrinol; 1984 Dec; 103(3):333-5. PubMed ID: 6150065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of PRL secretion by combined treatment with cyproterone acetate and ethinylestradiol.
    Valenti G; Vescovi PP; Gerra G; Rastelli G; Butturini U
    J Endocrinol Invest; 1985 Jun; 8(3):269-72. PubMed ID: 3161934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolactin and thyrotropin response to blockade of dopamine synthesis by monoiodotyrosine in subjects with postpartum and pathological hyperprolactinemia.
    Ghigo E; Ciccarelli E; Novelli A; Massobrio M; Müller EE; Camanni F
    J Endocrinol Invest; 1985 Feb; 8(1):35-40. PubMed ID: 3989236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopaminergic control of gonadotrophin secretion in normal women and in patients with pathological hyperprolactinaemia.
    Ho KY; Smythe GA; Lazarus L
    Clin Endocrinol (Oxf); 1984 Jan; 20(1):53-63. PubMed ID: 6420095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.
    Di Sarno A; Landi ML; Marzullo P; Di Somma C; Pivonello R; Cerbone G; Lombardi G; Colao A
    Clin Endocrinol (Oxf); 2000 Jul; 53(1):53-60. PubMed ID: 10931080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dysfunction of dopaminergic regulation of prolactin in patients with functioning and nonfunctioning pituitary adenomas and craniopharyngiomas.
    Martinez-Campos A; Cornejo J; Garza-Flores J; Velasco F
    Fertil Steril; 1985 Oct; 44(4):471-7. PubMed ID: 4054318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies on the prolactin-releasing capacity of luteinizing hormone releasing hormone in male subjects.
    Gooren LJ; Harmsen-Louman W; van Bergeyk L; van Kessel H
    Exp Clin Endocrinol; 1985 Dec; 86(3):300-4. PubMed ID: 3912199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low recurrence rate after partial hypophysectomy for prolactinoma: the predictive value of dynamic prolactin function tests.
    Webster J; Page MD; Bevan JS; Richards SH; Douglas-Jones AG; Scanlon MF
    Clin Endocrinol (Oxf); 1992 Jan; 36(1):35-44. PubMed ID: 1559298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced hypothalamic dopaminergic inhibition of LH, TSH and GH release in patients with pathological hyperprolactinaemia.
    Ho KY; Smythe GA; Lazarus L
    Acta Endocrinol (Copenh); 1985 Mar; 108(3):289-96. PubMed ID: 3984660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones.
    Asscheman H; Giltay EJ; Megens JA; de Ronde WP; van Trotsenburg MA; Gooren LJ
    Eur J Endocrinol; 2011 Apr; 164(4):635-42. PubMed ID: 21266549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study of 226 patients with histologically verified non-functioning pituitary macroadenoma.
    Karavitaki N; Thanabalasingham G; Shore HC; Trifanescu R; Ansorge O; Meston N; Turner HE; Wass JA
    Clin Endocrinol (Oxf); 2006 Oct; 65(4):524-9. PubMed ID: 16984247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopamine responsiveness of human prolactinoma cells as determined by the reverse hemolytic plaque assay.
    Kojima Y; Arita J; Kuwana N; Kimura F
    Endocr J; 1995 Jun; 42(3):355-60. PubMed ID: 7670564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolactin decrease and shift to a normal-like isoform profile during treatment with quinagolide in a patient affected by an invasive prolactinoma.
    Guido R; Valenti S; Foppiani L; De Martini D; Cossu M; Giusti M
    J Endocrinol Invest; 1997 May; 20(5):289-93. PubMed ID: 9258810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zinc and bromocriptine long-term administration in patients with prolactinomas: effects on prolactin and thymulin circulating levels.
    Travaglini P; Mocchegiani E; De Min C; Re T; Fabris N; Faglia G
    Int J Neurosci; 1991 Jul; 59(1-3):119-25. PubMed ID: 1774132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The outcome of hypophysectomy for prolactinomas in the era of dopamine agonist therapy.
    Soule SG; Farhi J; Conway GS; Jacobs HS; Powell M
    Clin Endocrinol (Oxf); 1996 Jun; 44(6):711-6. PubMed ID: 8759184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.
    Colao A; Ferone D; Lastoria S; Cerbone G; Di Sarno A; Di Somma C; Lucci R; Lombardi G
    Clin Endocrinol (Oxf); 2000 Apr; 52(4):437-45. PubMed ID: 10762286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.